GIM
XERS icon

Glenmede Investment Management’s Xeris Biopharma Holdings XERS Stock Holding History

Glenmede Investment Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-975
Closed -$4.55K – 1582
2025
Q2 		$4.55K Buy
+975
New +$4.47K ﹤0.01% 1473

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Glenmede Investment Management's XERS Position: Q3 2025 in Review

Glenmede Investment Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 975 shares — an estimated $4.55K sold.

Glenmede Investment Management first reported a position in XERS in Q2 2025 and held it in 1 quarter. The position peaked at $4.55K in Q2 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • Glenmede Investment Management reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 975 Xeris Biopharma Holdings shares in Q3 2025, an estimated $4.55K.
  • Glenmede Investment Management first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Xeris Biopharma Holdings position peaked at $4.55K in Q2 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.